SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Tissue Samples
2.2. Tissue Microarrays
2.3. Immunohistochemistry
2.4. Statistics
3. Results
3.1. Association between SCARA5 Expression and THSD7A-Positivity
3.2. Association between SCARA5 Expression and FAK Expression
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- The Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. Cell 2015, 163, 1011–1025. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wilt, T.J.; Brawer, M.K.; Jones, K.M.; Barry, M.J.; Aronson, W.J.; Fox, S.; Gingrich, J.R.; Wei, J.T.; Gilhooly, P.; Mayer Grob, B.; et al. Radical Prostatectomy versus Observation for Localized Prostate Cancer. N. Engl. J. Med. 2012, 367, 203–216. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Litwin, M.S.; Tan, H.J. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA 2017, 317, 2532–2542. [Google Scholar] [CrossRef] [PubMed]
- Stahl, P.R.; Hoxha, E.; Wiech, T.; Schröder, C.; Simon, R.; Stahl, R.A. THSD7A expression in human cancer. Genes Chromosom. Cancer 2017, 56, 314–327. [Google Scholar] [CrossRef]
- Flockerzi, F.A.; Hohneck, J.; Saar, M.; Bohle, R.M.; Stahl, P.R. THSD7A Positivity Is Associated with High Expression of FAK in Prostate Cancer. Diagnostics 2023, 13, 221. [Google Scholar] [CrossRef]
- Wang, C.H.; Su, P.T.; Du, X.Y.; Kuo, M.W.; Lin, C.Y.; Yang, C.C.; Chan, H.S.; Chang, S.J.; Kuo, C.; Seo, K.; et al. Thrombospondin type I domain containing 7A (THSD7A) mediates endothelial cell migration and tube formation. J. Cell. Physiol. 2010, 222, 685–694. [Google Scholar] [CrossRef]
- Kuo, W.; Wang, C.-H.; Wu, H.-C.; Chang, S.-J.; Chuang, Y.-J. Soluble THSD7A Is an N-Glycoprotein That Promotes Endothelial Cell Migration and Tube Formation in Angiogenesis. PLoS ONE 2011, 6, e2900. [Google Scholar] [CrossRef]
- Wang, C.-H.; Chen, I.-H.; Kuo, M.-W.; Su, P.-T.; Lai, Z.-Y.; Wang, C.-H.; Huang, W.-C.; Hoffman, J.; Kuo, C.J.; You, M.-S.; et al. Zebrafish Thsd7a Is a Neural Protein Required for Angiogenic Patterning During Development. Dev. Dyn. 2011, 240, 1412–1421. [Google Scholar] [CrossRef]
- Aktepe, O.H.; Koray Sahin, T.; Guner, G.; Can Guven, D.; Hasan Yeter, H.; Kurtulan, O.; Ozercan, I.H.; Dizdar, O.; Yalcin, S. Correlation Between THSD7A Expression and Tumor Characteristics of Azoxymethane-Induced Colon Cancer Model in Rats. Turk. J. Gastroenterol. 2021, 32, 1049–1056. [Google Scholar] [CrossRef]
- Aktepe, O.H.; Gundogdu, F.; Kosemehmetoglu, K.; Yeter, H.H.; Aksoy, S.; Guven, D.C.; Sahin, T.K.; Yuce, D.; Kertmen, N.; Dizdar, O.; et al. THSD7A expression: A novel immunohistochemical determinant in predicting overall survival of metastatic renal cell carcinoma treated with targeted therapy. Ir. J. Med. Sci. 2022, 191, 1561–1567. [Google Scholar] [CrossRef] [PubMed]
- Xian, L.; Dong, D.; Luo, J.; Zhuo, L.; Li, K.; Zhang, P.; Wang, W.; Xu, Y.; Xu, G.; Wang, L.; et al. Expression of THSD7A in neoplasm tissues and its relationship with proteinuria. BMC Nephrol. 2019, 20, 332. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hou, Z.; Abudureheman, A.; Wang, L.; Hasim, A.; Ainiwaer, J.; Zhang, H.; Niyaz, M.; Upur, H.; Sheyhidin, I. Expression, prognosis and functional role of Thsd7a in esophageal squamous cell carcinoma of Kazakh patients, Xinjiang. Oncotarget 2017, 8, 60539–60557. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oishi, M.; Munesue, S.; Harashima, A.; Nakada, M.; Yamamoto, Y.; Hayashi, Y. Aquaporin 1 elicits cell motility and coordinates vascular bed formation by downregulating thrombospondin type-1 domain-containing 7A in glioblastoma. Cancer Med. 2020, 9, 3904–3917. [Google Scholar] [CrossRef] [Green Version]
- Lin, F.; Zhang, D.; Chang, J.; Tang, X.; Guan, W.; Jiang, G.; Zhu, C.; Bian, F. THSD7A-associated membranous nephropathy in a patient with neurofibromatosis type 1. Eur. J. Med. Genet. 2018, 61, 84–88. [Google Scholar] [CrossRef]
- Lin, X.; Kapoor, A.; Gu, Y.; Chow, M.J.; Peng, J.; Major, P.; Tang, D. cancers Construction of a Novel Multigene Panel Potently Predicting Poor Prognosis in Patients with Clear Cell Renal Cell Carcinoma. Cancers 2020, 12, 3471. [Google Scholar] [CrossRef]
- Chen, M.; Zhang, L.; Zhong, W.; Zheng, K.; Ye, W.; Wang, M. Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient. Front. Immunol. 2021, 12, 619147. [Google Scholar] [CrossRef]
- Zhang, D.; Zhang, C.; Bian, F.; Zhang, W.; Jiang, G.; Zou, J. Clinicopathological features in membranous nephropathy with cancer: A retrospective single-center study and literature review. Int. J. Biol. Markers 2019, 34, 406–413. [Google Scholar] [CrossRef]
- Taguchi, S.; Koshikawa, Y.; Ohyama, S.; Miyachi, H.; Ozawa, H.; Asada, H. Thrombospondin type-1 domain-containing 7A-associated membranous nephropathy after resection of rectal cancer: A case report. BMC Nephrol. 2019, 20, 43. [Google Scholar] [CrossRef] [Green Version]
- Cance, W.G.; Harris, J.E.; Iacocca, M.V.; Roche, E.; Yang, X.; Chang, J.; Simkins, S.; Xu, L. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: Correlation with preinvasive and invasive phenotypes. Clin. Cancer Res. 2000, 6, 2417–2423. [Google Scholar]
- Canel, M.; Secades, P.; Rodrigo, J.-P.; Cabanillas, R.; Herrero, A.; Suarez, C.; Chiara, M.-D. Overexpression of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma Is Independent of fak Gene Copy Number. Clin. Cancer Res. 2006, 12, 3272–3279. [Google Scholar] [CrossRef] [Green Version]
- Ocak, S.; Chen, H.; Callison, C.; Gonzalez, A.L.; Massion, P.P. Expression of Focal Adhesion Kinase in Small-Cell Lung Carcinoma. Cancer 2012, 118, 1293–1301. [Google Scholar] [CrossRef]
- Yoon, H.; Dehart, J.P.; Murphy, J.M.; Lim, S.T. Understanding the roles of FAK in cancer: Inhibitors, genetic models, and new insights. J. Histochem. Cytochem. 2015, 63, 114–128. [Google Scholar] [CrossRef] [Green Version]
- Halder, J.; Lin, Y.G.; Merritt, W.M.; Spannuth, W.A.; Nick, A.M.; Honda, T.; Kamat, A.A.; Han, L.Y.; Kim, T.J.; Lu, C.; et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res. 2007, 67, 10976–10983. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Walsh, C.; Tanjoni, I.; Uryu, S.; Tomar, A.; Nam, J.-O.; Luo, H.; Phillips, A.; Patel, N.; Kwok, C.; McMahon, G.; et al. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol. Ther. 2010, 9, 778–790. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Golubovskaya, V.M.; Figel, S.; Ho, B.T.; Johnson, C.P.; Yemma, M.; Huang, G.; Zheng, M.; Nyberg, C.; Magis, A.; Ostrov, D.A.; et al. A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo. Carcinogenesis 2012, 33, 1004–1013. [Google Scholar] [CrossRef] [PubMed]
- Dai, F.; Chen, Y.; Huang, L.; Wang, J.; Zhang, T.; Li, J.; Tong, W.; Liu, M.; Yi, Z. A novel synthetic small molecule YH-306 suppresses colorectal tumour growth and metastasis via FAK pathway. J. Cell Mol. Med. 2015, 19, 383–395. [Google Scholar] [CrossRef]
- Du, C.; Zheng, Z.; Li, D.; Chen, L.; Li, N.; Yi, X.; Yang, Y.; Liu, W.; Xie, X.; Xie, M. BKCa promotes growth and metastasis of prostate cancer through facilitating the coupling between αvβ3 integrin and FAK. Oncotarget 2016, 7, 40174–40188. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kung, H.-J. Targeting tyrosine kinases and autophagy in prostate cancer. Horm. Cancer 2011, 2, 38–46. [Google Scholar] [CrossRef] [Green Version]
- Slack-Davis, J.K.; Daniel Hershey, E.; Theodorescu, D.; Frierson, H.F.; Parsons, J.T. Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol. Cancer Ther. 2009, 8, 2470–2477. [Google Scholar] [CrossRef] [Green Version]
- Jumai, K.; Zhang, T.; Qiao, B.; Ainiwaer, J.; Zhang, H.; Hou, Z.; Awut, I.; Niyaz, M.; Zhang, L.; Sheyhidin, I. Highly Expressing SCARA5 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma. J. Immunol. Res. 2022, 2022, 2555647. [Google Scholar] [CrossRef] [PubMed]
- Yu, B.; Cheng, C.; Wu, Y.; Guo, L.; Kong, D.; Zhang, Z.; Wang, Y.; Zheng, E.; Liu, Y.; He, Y. Interactions of ferritin with scavenger receptor class A members. J. Biol. Chem. 2020, 295, 15727–15741. [Google Scholar] [CrossRef] [PubMed]
- Liu, J.; Zeng, M.L.; Shi, P.C.; Cao, Y.P.; Zhang, J.L.; Xie, Y.P. SCARA5 is a Novel Biomarker in Colorectal Cancer by Comprehensive Analysis. Clin. Lab. 2020, 66, 1227–1236. [Google Scholar] [CrossRef] [PubMed]
- Xu, Z.; Hong, Z.; Ma, M.; Liu, X.; Chen, L.; Zheng, C.; Xi, X.; Shao, J. Rock2 promotes RCC proliferation by decreasing SCARA5 expression through β-catenin/TCF4 signaling. Biochem. Biophys. Res. Commun. 2016, 480, 586–593. [Google Scholar] [CrossRef] [PubMed]
- Ulker, D.; Ersoy, Y.E.; Gucin, Z.; Muslumanoglu, M.; Buyru, N. Downregulation of SCARA5 may contribute to breast cancer via promoter hypermethylation. Gene 2018, 673, 102–106. [Google Scholar] [CrossRef]
- Liu, Y.; Tan, Y.-R.; Sun, W.-W.; Ju, W.-T.; Fu, Y.; Wang, L.-Z.; Li, J.; Zhang, C.-P.; Zhang, Z.-Y.; Zhong, L.-P. Identification of SCARA5 as a Potential Biomarker for Oral Squamous Cell Carcinoma using MALDI-TOF-MS Analysis. Proteom. Clin. Appl. 2018, 12, e1700180. [Google Scholar] [CrossRef]
- Huang, J.; Lv, C.; Zhao, B.; Ji, Z.; Gao, Z. SCARA5 inhibits oral squamous cell carcinoma via inactivating the STAT3 and PI3K/AKT signaling pathways. Open Med. 2023, 18, 20230627. [Google Scholar] [CrossRef]
- Li, Y.; Peng, F.; Tan, X.; Wang, J.; Xu, Y. Tumor suppressive effect of scavenger receptor class A member 5 overexpression in colorectal cancer by regulating PI3K/AKT/mTOR pathway. Genes Genom. 2021, 43, 1189–1198. [Google Scholar] [CrossRef]
- Khamas, A.; Ishikawa, T.; Shimokawa, K.; Mogushi, K.; Iida, S.; Ishiguro, M.; Mizushima, H.; Tanaka, H.; Uetake, H.; Sugihara, K. Screening for epigenetically masked genes in colorectal cancer Using 5-Aza-2′-deoxycytidine, microarray and gene expression profile. Cancer Genom. Proteom. 2012, 9, 67–75. [Google Scholar]
- Wang, F.; Cao, X.; Yin, L.; Wang, Q.; He, Z. Identification of SCARA5 Gene as a Potential Immune-Related Biomarker for Triple-Negative Breast Cancer by Integrated Analysis. DNA Cell Biol. 2020, 39, 1813–1824. [Google Scholar] [CrossRef]
- You, K.; Su, F.; Liu, L.; Lv, X.; Zhang, J.; Zhang, Y.; Liu, B. SCARA5 plays a critical role in the progression and metastasis of breast cancer by inactivating the ERK1/2, STAT3, and AKT signaling pathways. Mol. Cell. Biochem. 2017, 435, 47–58. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.; Liu, C.; Wang, X.; Wang, Y.; Zheng, J. SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression. J. Cancer 2021, 12, 2412–2421. [Google Scholar] [CrossRef] [PubMed]
- Wen, X.; Wang, N.; Zhang, F.; Dong, C. Overexpression of SCARA5 inhibits tumor proliferation and invasion in osteosarcoma via suppression of the FAK signaling pathway. Mol. Med. Rep. 2016, 13, 2885–2891. [Google Scholar] [CrossRef] [Green Version]
- Liu, J.; Hu, G.; Chen, D.; Gong, A.-Y.; Soori, G.S.; Dobleman, T.J.; Chen, X.-M. Suppression of SCARA5 by Snail1 is essential for EMT-associated cell migration of A549 cells. Oncogenesis 2013, 2, e73. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, J.; Zheng, D.-L.; Qin, F.-S.; Cheng, N.; Chen, H.; Wan, B.-B.; Wang, Y.-P.; Xiao, H.-S.; Han, Z.-G. Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. J. Clin. Investig. 2010, 120, 223–241. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yan, N.; Zhang, S.; Yang, Y.; Cheng, L.; Li, C.; Dai, L.; Dai, L.; Zhang, X.; Fan, P.; Tian, H.; et al. Therapeutic upregulation of Class A scavenger receptor member 5 inhibits tumor growth and metastasis. Cancer Sci. 2012, 103, 1631–1639. [Google Scholar] [CrossRef]
- Zhang, X.; Liu, Y.; Fan, C.; Wang, L.; Li, A.; Zhou, H.; Cai, L.; Miao, Y.; Li, Q.; Qiu, X.; et al. Lasp1 promotes malignant phenotype of non-small-cell lung cancer via inducing phosphorylation of FAK-AKT pathway. Oncotarget 2017, 8, 75102–75113. [Google Scholar] [CrossRef] [Green Version]
- Liu, H.; Hu, J.; Pan, H.; Luo, D.; Huang, M.; Xu, W. CSN5 Promotes Hepatocellular Carcinoma Progression by SCARA5 Inhibition Through Suppressing β-Catenin Ubiquitination. Dig. Dis. Sci. 2018, 63, 155–165. [Google Scholar] [CrossRef]
- Ni, Q.; Li, X.; Huang, H.; Ge, Z. Decreased expression of SCARA5 predicts a poor prognosis in melanoma using bioinformatics analysis. Front. Oncol. 2023, 13, 1015358. [Google Scholar] [CrossRef]
SCARA5 | |||
---|---|---|---|
Low | High | p | |
pT-status | <0.001 | ||
pT2 | 109 | 67 | |
pT3–pT4 | 69 | 119 | |
Nodal status | <0.001 | ||
pN0 | 149 | 118 | |
pN+ | 26 | 65 | |
WHO grade group | <0.001 | ||
1 | 41 | 27 | |
2 | 56 | 28 | |
3 | 39 | 46 | |
4 | 37 | 74 | |
5 | 5 | 11 |
SCARA5 | |||
---|---|---|---|
Low | High | p | |
THSD7A | 0.6 | ||
negative | 148 | 151 | |
positive | 15 | 19 |
SCARA5 | |||
---|---|---|---|
Negative, Weak, Moderate | Strong | p | |
THSD7A | 0.016 | ||
negative | 272 | 27 | |
positive | 26 | 8 |
SCARA5 | |||
---|---|---|---|
Low | High | p | |
FAK | 0.4 | ||
low | 96 | 90 | |
high | 55 | 64 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Flockerzi, F.A.; Hohneck, J.; Saar, M.; Bohle, R.M.; Stahl, P.R. SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis. Diagnostics 2023, 13, 2211. https://doi.org/10.3390/diagnostics13132211
Flockerzi FA, Hohneck J, Saar M, Bohle RM, Stahl PR. SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis. Diagnostics. 2023; 13(13):2211. https://doi.org/10.3390/diagnostics13132211
Chicago/Turabian StyleFlockerzi, Fidelis Andrea, Johannes Hohneck, Matthias Saar, Rainer Maria Bohle, and Phillip Rolf Stahl. 2023. "SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis" Diagnostics 13, no. 13: 2211. https://doi.org/10.3390/diagnostics13132211